# RAD VACCINE MIBC (NCT05241340)

> Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer

No report yet. It can be ordered.

- Drugs tested: sasanlimab plus stereotactic body radiation therapy
- Indication: cisplatin-ineligible muscle invasive bladder cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05241340
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: The Methodist Hospital Research Institute
- Conditions: Urothelial Carcinoma Bladder
- Interventions: Sasanlimab; Stereotactic Body Radiation Therapy; Radical Cystectomy + pelvic lymph node dissection + urinary diversion
- Enrollment: 33
- Primary outcome: Composite outcome for Feasibility and Safety
- Primary outcome: Clinical benefit rate defined as pathologic complete response (pT0)

## Indexed commentary on RAD VACCINE MIBC so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=rad-vaccine-mibc-nct05241340